Drug Trial Radar · NCT07895355
Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
412
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jul 2028
Study completion Jan 2030
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer
Conditions
- Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy
Interventions
RC148 plus Telisotuzumab adizutecanDrug
Dose 1/ Dose 1
RC148 plus Telisotuzumab adizutecanDrug
Dose 2/ Dose 1
RC148 plus Telisotuzumab adizutecanDrug
Dose 3/ Dose 2
RC148 plus Telisotuzumab adizutecanDrug
Dose 2/ Dose 2
Telisotuzumab adizutecan plus BevacizumabDrug
Dose 1
Telisotuzumab adizutecan plus BevacizumabDrug
Dose 2
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR as assessed by the Investigator per RECIST v1.1Time frame: From randomization date until disease progression, lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months
- The incidence and severity of AEs, vital signs, physical examinations, ECGs, and laboratory testTime frame: Screening through 120 days after the last dose of RC148/telisotuzumab adizutecan/bevacizumab or 28 days after the last dose of 5-FU/LV, whichever is late
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangdong, Guangzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.